Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab in Adult Chinese Patients With Tumor-induced Osteomalacia
CTR20221268Phase 4Completed
- Sponsor
- Kyowa Kirin
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of burosumab in tumor-induced osteomalacia (TIO), sponsored by Kyowa Kirin. Started May 2022; status: completed.
02
Drugs
burosumab
03
Conditions
tumor-induced osteomalacia (TIO)
Beyond the preview
Go deeper on CTR20221268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221268.